Re-Exam Can't Save Allergan Eye Drop IP, Fed. Circ. Says
The Federal Circuit on Friday affirmed a lower court's ruling that the patent covering Allergan Inc.'s eye drop Zymar is invalid as obvious, even after the company amended the claims in...To view the full article, register now.
Already a subscriber? Click here to view full article